Revolution Medicines (RVMD) said Wednesday the first patient has been dosed in a phase 3 trial evaluating daraxonrasib in patients with previously treated, locally advanced or metastatic RAS mutant non-small cell lung cancer compared to docetaxel chemotherapy.
The trial is expected to enroll around 420 patients, with dual primary endpoints of progression-free survival and overall survival, the company said.
The decision to evaluate daraxonrasib as a monotherapy was informed by early evidence from a single-arm trial showing that the compound had an acceptable safety profile and encouraging antitumor activity, the company said.
Revolution Medicines' shares rose by more than 2% in premarket trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。